• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Cochrane Review: Oral or Intra-Vaginal Anti-Fungal Treatment for Candidiasis?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • This Cochrane review by Denison et al. (Cochrane Database Sys Rev, 2020) is the second update of the original review
  • The authors assessed the effectiveness of oral versus intravaginal antifungals for the treatment of uncomplicated vulvovaginal candidiasis

METHODS:

  • Systematic review and meta-analysis
  • Inclusion criteria
    • RCTs
    • Any language
    • Trials that compared at least one oral antifungal with one intravaginal antifungal
    • Participants: Women ≥ 16 years  | Positive mycological diagnosis of uncomplicated vulvovaginal candidiasis
    • Exclusion: HIV positive | Imunocompromised | Pregnant | Breast feeding | Diabetic
  • Primary outcome
    • Relative effectiveness of clinical cure (presence of symptoms)
  • Secondary outcomes
    • Relative effectiveness for mycological cure
    • Safety | Side effects | Treatment preference | Time to first relief of symptoms | Costs

RESULTS:

  • 26 trials | 5007 participants
    • Trials were conducted in multiple countries
    • Overall risk of bias deemed to be high
    • 8 different medications were included (imidazole and triazole)

Oral vs Intravaginal Antifungals for Clinical Cure

  • There was probably little or no difference between oral and intravaginal anti-fungal treatment for clinical cure
    • Short-term follow-up (5 to 15 days)
      • Odds ratio (OR) 1.14 (95% CI, 0.91 to 1.43; 13 trials; 1859 participants)
      • Moderate-certainty evidence
    • Long-term follow-up (2 to 12 weeks)
      • OR 1.07 (95% CI, 0.77 to 1.50; 9 trials; 1042 participants)
      • Moderate-certainty evidence
  • Oral treatment probably improves mycological cure over intravaginal treatment at
    • Short-term follow-up
      • OR 1.24 (95% CI, 1.03 to 1.50: 19 trials; 3057 participants)
      • Moderate-certainty evidence
    • Long-term follow-up
      • OR 1.29 (95% CI, 1.05 to 1.60; 13 trials; 1661 participants)
      • Moderate-certainty evidence

Oral vs IntraVaginal Antifungals for Safety and Satisfaction

  • Safety
    • Low risk of participants withdrawing from the studies due to adverse drug effects for either treatment
      • 23 trials; 4637 participants
      • High-certainty evidence
    • It is undetermined whether oral treatments reduced the number of side effects compared with intravaginal treatments
      • OR 1.04 (95% CI, 0.84 to 1.29; 16 trials; 3155 participants)
      • Low-certainty evidence
    • The type of side effects differed
      • Intravaginal: Local reactions
      • Oral: Systemic effects | Especially GI symptoms and headaches
  • Patient satisfaction
    • Oral treatment was favored by participants
      • 12 trials; 2206 participants
      • Low-certainty evidence
    • Little or no difference in time to first relief of symptoms was seen between oral vs intravaginal treatments
      • 10 trials; 1910 participants
      • Low-certainty evidence
  • Costs were not reported in any trial

CONCLUSION:

  • Compared to intra-vaginal anti-fungal treatment, oral treatment does not appear to make a difference when it comes to clinical cure (perceived symptoms) but probably does improve clearance of candida from vaginal canal when compared to vaginal treatment
  • Oral treatment was also preferred by participants, though certainty of evidence was low
  • Upon review of these the results, Cochrane Reviews states that

The addition of new evidence does not change the conclusions of the review. The results of this review should be considered stable in terms of the antifungal medicines included. The frequency of future updates should be limited. No further updates are planned

Learn More – Primary Sources:

Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Are Probiotics Useful for the Treatment of Vulvovaginal Candidiasis?
Are Vaginal Antimycotics Associated with an Increased Risk for Miscarriage?
Diagnosis and Treatment of Vulvovaginal Candidiasis

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site